Form 4: Prelude Therapeutics CEO Granted Stock Options
SEC Form 4
Krishna Vaddi, CEO of Prelude Therapeutics, was granted stock options for 496,000 shares on February 4, 2025, vesting over a period of four years.
Summary
- Krishna Vaddi, CEO of Prelude Therapeutics, filed a Form 4 on February 5, 2025, reporting a transaction.
- On February 4, 2025, Vaddi was granted employee stock options for 496,000 shares of Prelude Therapeutics common stock at an exercise price of $1.11.
- The options vest as to 25% on February 4, 2026, and then 1/48 monthly until fully vested, contingent on continued service to the company.
- The options expire on February 4, 2035.
Sentiment
Score: 7
Explanation: The document itself is neutral, simply reporting a stock option grant. However, the grant itself can be seen as a positive sign, indicating confidence in the CEO's ability to lead the company and increase shareholder value.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's financial performance or future prospects, but the stock option grant suggests an expectation of continued service and value creation by the CEO.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders. The size and vesting schedule of the grant are typical for a CEO of a company of Prelude Therapeutics' size and stage.
Comparison to Industry Standards
- Stock option grants to CEOs in the pharmaceutical industry typically range from 1x to 5x their base salary.
- Vesting schedules are usually over a 3-5 year period, with a cliff vesting period of 1 year.
- Comparable companies such as Deciphera Pharmaceuticals, Blueprint Medicines, and Relay Therapeutics also utilize stock options as part of their executive compensation packages.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning the CEO's interests with their own.
- Employees may be motivated by the CEO's commitment to the company.
Key Dates
| Date | Description |
|---|---|
| February 3, 2025 | Date of Power of Attorney execution. |
| February 4, 2025 | Date of stock option grant. |
| February 4, 2026 | First vesting date for 25% of the stock options. |
| February 4, 2035 | Expiration date of the stock options. |
| February 5, 2025 | Date Form 4 was signed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.